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Background: Adenosine-5′-triphosphate (ATP) is a neurotransmitter and inflammatory cytokine implicated in the
pathophysiology of lower urinary tract disease. ATP additionally reflects microbial biomass thus has potential as a
surrogate marker of urinary tract infection (UTI). The optimum clinical sampling method for ATP urinalysis has not
been established. We tested the potential of urinary ATP in the assessment of lower urinary tract symptoms,
infection and inflammation, and validated sampling methods for clinical practice.
Methods: A prospective, blinded, cross-sectional observational study of adult patients presenting with lower urinary
tract symptoms (LUTS) and asymptomatic controls, was conducted between October 2009 and October 2012. Urinary
ATP was assayed by a luciferin-luciferase method, pyuria counted by microscopy of fresh unspun urine and symptoms
assessed using validated questionnaires. The sample collection, storage and processing methods were also validated.
Results: 75 controls and 340 patients with LUTS were grouped as without pyuria (n = 100), pyuria 1-9 wbc μl-1
(n = 120) and pyuria ≥10 wbc μl-1 (n = 120). Urinary ATP was higher in association with female gender, voiding
symptoms, pyuria greater than 10 wbc μl-1 and negative MSU culture. ROC curve analysis showed no evidence of
diagnostic test potential. The urinary ATP signal decayed with storage at 23°C but was prevented by immediate
freezing at≤ -20°C, without boric acid preservative and without the need to centrifuge urine prior to freezing.
Conclusions: Urinary ATP may have a role as a research tool but is unconvincing as a surrogate, clinical diagnostic
marker.
Keywords: Lower urinary tract symptoms (LUTS), Adenosine-5′-triphosphate (ATP), Urinary tract infection (UTI)Background
“Lower Urinary Tract Symptoms” (LUTS) is a collective
term describing [1] urinary storage problems such as fre-
quency, urgency and urge incontinence; [2] voiding diffi-
culties such as hesitancy, reduced stream, intermittency
and incomplete voiding; [3] sensory symptoms that
include various experiences of pain; and [4] stress urinary
incontinence. There is considerable overlap between these
symptoms [1] so that diagnostic categorisation is difficult.* Correspondence: kiren.gill@ucl.ac.uk
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unless otherwise stated.Whatever the symptom mix, the exclusion of urinary tract
infection (UTI) is a mandatory first step in the assessment
of all LUTS [2]. Whilst acute UTI is not diagnostically
challenging, in the case of LUTS without acute fre-
quency and dysuria, exclusion of infection poses a diag-
nostic challenge.
There are good reasons to scrutinise urinary adenosine-
5′-triphosphate (ATP) as a possible surrogate marker of
UTI since the reliability of popular diagnostic methods
used to exclude UTI have been questioned [3-6]. Pub-
lished guidelines across Europe, USA and the UK reveal
significant discrepancies in the choice of a quantitative
threshold used to define significant bacteriuria. The clean-
catch, midstream urine (MSU) sample culture in the UK
and Europe commonly uses the Kass (1957) [7] criterions is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Gill et al. BMC Urology  (2015) 15:7 Page 2 of 9of 105 colony forming units (cfu) ml-1 of a single species
of a known urinary pathogen. Kass drew these data from
74 women with acute pyelonephritis and 337 normal
controls, a select sample unrepresentative of wider lower
urinary tract symptoms (LUTS). Despite its limitations,
this criterion has become a ubiquitous reference standard
and has been challenged by several groups [6,8]. The
European Associate of Urology (EUA) guidelines for uro-
logical infections emphasise that no single threshold can
be applied in all clinical situations. The urinary dipstick
tests for nitrite and leucocyte esterase are also commonly
used as a bedside screening test for infection and as a
measure of a positive urine culture. However the use of
urinary dipstick have been validated against the urine
culture to a threshold of 105 colony forming units (cfu)
ml-1 and given the recent criticism of the Kass criterion,
urinary dipstick have also recently been found to be unre-
liable [3,4,9].
Urinary tract ATP has attracted intense interest in the
last 30 years for its pharmacological and pathophysio-
logical associations. There are great hopes that puriner-
gic receptor manipulation might influence detrusor motor
function and urothelial afferents [10], achieving thera-
peutic benefit. ATP is an important urothelial cell distress
signal [11] and is released by inflammatory cells and bac-
teria [12]. Urinary tract infection featuring bacterial inva-
sion, urothelial distress and an innate immune response
involving recruitment of inflammatory cells, should be as-
sociated with increased urinary ATP levels. Indeed, high
levels of ATP have been detected in the urine of patients
with interstitial cystitis and acute UTI with a positive
urine culture [13]. Increased ATP has also been shown to
be released from cultured urothelial cells infected with
uropathogenic E.coli (UPEC) [14], and UPEC also produce
ATP when cultured in vitro [15]. It has been postulated
that ATP may reflect microbial biomass and hence ATP
increases as the amount of bacteria present increases.
Currently ATP levels are used widely in the food, water
and sanitation industry as a measure of bacterial contam-
ination [16].
Given the problems with current tests [3], developing
alternative diagnostic assays is a high priority. We there-
fore sought to scrutinise the performance of urinary ATP
to test for potential as a surrogate measure of inflamma-
tion and infection when assessing patients with chronic
LUTS. The experiment was divided into two parts; [1] a
clinical experiment that evaluated urinary ATP in patients
with LUTS and controls, comparing urinary ATP with
symptoms, microscopic pyuria and urine culture results;
and [2] a laboratory experimental series that explored the
factors that could influence sample collection, storage
and preservation. As urine contains native ATPase activ-
ity, the time-decay curve of urinary ATP from collection
to processing was evaluated. Boric acid crystals, whichare commonly used as a urinary preservative, have been
shown to prevent microbial swarming [17] and boric acid
has a preservative influence on white cells [18]. We there-
fore studied the effects of the use of urinary preservative
boric acid, storage temperature and the effect of centrifu-
gation on urinary ATP concentration.
Methods
Ethical approval
Ethical committee approval for this study, including all
study documentation, was obtained from the Whittington
and Moorefields Research Ethics Committee. All study
participants gave informed written consent to participate
in the study and the process was documented as per Good
Clinical Practice (GCP) and MHRA guidelines. The par-
ticipants were assigned randomly generated study num-
bers which were used to anonymise all data and samples,
and analysis was carried out by blinded researchers.
Patients and symptom collection
Adult patients presenting with lower urinary tract symp-
toms were recruited from incontinence clinics from October
2009 to October 2012 and informed consent obtained. We
compared urine samples from 75 healthy controls and 340
patients presenting with LUTS. The demographic data
can be seen in Table 1. The control group consisted of 49
females and 26 males, with mean age 38.2 yrs (95% CI
34.5 - 41.8). Within the LUTS group there were 314 fe-
males and 26 males, with a mean age of 58.6 yrs (95% CI
56.8 - 60.4). All patients completed detailed validated
LUTS questionnaires covering 38 symptoms, including
frequency, nocturia, urgency, incontinence episodes, symp-
toms relating to storage function, voiding problems, stress
urinary incontinence and pain, which were recorded on a
bespoke clinical database. Control subjects completed
questionnaires thereby confirming absence of symptoms.
There are popular, validated symptom scores such as the
ICIQ series [19] which are suitable as intervention out-
come measures because changes in individual scores can
be normalised for group comparisons. However, adjectival
scaling such as ‘bother’, when deployed in cross-sectional,
descriptive work, is vulnerable to semantic interpretation
differences, and considerable error may occur [20]. To
avoid this, we used validated scales that measure symp-
toms dichotomously and achieve scaling by counting the
contexts in which symptoms occur. These are effective
measures for cross-sectional observation studies [21-23].
Midstream urine (MSU) collection
Samples were obtained by the midstream clean-catch
method. Patients were given detailed instruction on how
to collect a meticulous midstream urine sample and avoid
perineal contamination. This included use of an antiseptic
wipe to clean the genital area prior to voiding and use of a
Table 1 Demographic data
Controls LUTS patients
Gender male N = 26 N = 26
Gender female N = 49 N = 314
No pyuria N = 58 (female = 35, male = 23) N = 100 (female = 92, male = 8)
Any pyuria N = 17 (female = 14, male = 3) N = 240 (female = 222, male = 18)
Mean Std deviation (sd) Mean Std deviation (sd)
Age (years) 38.2 15.8 58.6 16.6
Mean Median sd Quartile range Mean Median sd Quartile range
24 hour frequency 6.2 6.2 6.0 to 7.0 6.0 to 7.0 9.2 8.0 8.0 to 10.0 6.0 to 11.0
24 hour incontinence 0 0 0.0 to 0.0 0.0 to 0.0 0.8 0.5 0.5 to 1.2 0.0 to 1.0
Number of urgency symptoms 0 0 0.0 to 0.0 0.0 to 0.0 2.8 2.0 2.0 to 3.6 0.0 to 4.0
Number of pain symptoms 0 0 0.0 to 0.0 0.0 to 0.0 0.4 0.0 0.2 to 0.6 0.0 to 0.0
Number of stress inc symptoms 0 0 0.0 to 0.0 0.0 to 0.0 0.3 0.0 0.08 to 0.5 0.0 to 0.0
Number of voiding symptoms 0 0 0.0 to 0.0 0.0 to 0.0 1.4 0.0 1.0 to 1.8 0.0 to 2.0
Number of LUTS 0 0 0.0 to 0.0 0.0 to 0.0 5.0 3.5 4.0 to 6.0 1.0 to 6.0
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urine mid-flow and removed before completion of voiding.
Routine urine culture
The urine was cultured using the Kass [7] threshold for
significance which is the standard method of analysis
in UK-NHS practice. A 1 μl loop of urine was plated
on a chromogenic agar plate and incubated at 37°C for
24 hours. Cultures were reported as positive if there was
bacterial growth of a single urinary pathogen of greater
than 105 cfu ml-1, negative bacterial growth if less than
105 cfu ml-1 and reported as mixed growth if there was
more than one uropathogen with total growth greater
than 105 cfu ml-1. Although 105 cfu ml-1 threshold is
known to be inadequate [6,3,24], we included it in this
study because it such a ubiquitous gold standard.
Microscopic leucocyte count
A fresh aliquot of urine was examined by microscopy.
10 μl of urine was loaded into a Neubauer haemocytom-
eter counting chamber [25] and examined by light micros-
copy (magnification x200) for leucocytes.
Blinding
Microscopy and ATP analysis were performed by researchers
blinded to the details or symptoms of the participants.
Samples presented for analysis were identified only by
a randomly generated four-digit study number.
ATP analysis
Samples were processed using Sigma-Aldrich Adenosine
5′-triphosphate (ATP) Bioluminescent Assay Kit, at an
approximate cost of £250, which is able to detect con-
centrations of 2 × 10-12 to 8 × 10-5 mol/L. Urine samplesstored at -80°C and -20°C were thawed in a water bath
in room temperature (23°C) and processed according to
the manufacturer’s instructions. Reagents were prepared
as per the manufacturer’s recommendation with measures
included to prevent degradation. The standard assay kit
(SigmaAldrich; Missouri, USA) applied a bioluminescent
reaction involving the breakdown of luciferin by luciferase,
which requires ATP. The average luminescence recorded,
in relative light units (RLU), was proportional to the con-
centration of ATP. This was converted to ATP moles ml-1
using a standard curve.
Evaluation of the effect of time on urinary ATP
Urine samples used to assess stability of ATP over time
were stored at room temperature (23°C). Aliquots were
taken at 0 hours (immediately), 12 hours, 24 hours, 48 hours,
168 hours and frozen at -80°C.
Evaluation of the effect of storage temperature on
urinary ATP
The literature tends to recommend storage at -80°C; how-
ever, this is not convenient for many clinical services. The
effects of freezing at -80°C and -20°C were therefore studied.
2 ml aliquots of fresh urine were taken from each partici-
pant. One aliquot was frozen immediately after micros-
copy and stored at -80°C and another at -20°C.
Evaluation of the use of boric acid preservative on
urinary ATP
We studied the effects of boric acid preservation on decay
of urinary ATP. 10mls of urine was introduced into pre-
prepared boric acid tubes (Becton Dickinson Vacutainer®
C & S Preservative Urine Tubes for Culture and Sensitivity)
and stored at room temperature. Aliquots were taken at
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168 hours and frozen at -80°C.
Evaluation of the effect of centrifugation on urinary ATP
Urinary ATP may originate from several sources includ-
ing bacteria, urothelial cells and white cells. Therefore,
we sought to discover whether centrifuging the urine al-
ters the assay result, either by removing cells from the
supernatant, or by lysing cells in the process [26]. An ali-
quot of urine was spun at 620 g for 5 minutes and the
supernatant was frozen at -80°C.
All of the urine aliquots for the clinical experiments
were frozen immediately at -80°C. These samples were
processed for urinary ATP between eight to twelve weeks
after collection and storage. The frozen urine aliquots
were thawed to room temperature (23°C) using a water
bath and then immediately analysed using the stand-
ard luciferin-luciferase assay and protocol, which was
described earlier.
Statistics
We used multivariate linear regression analyses to scrutin-
ise the log10 ATP as the response variable using two
models. In the first, the explanatory variables were gender
(0 = female, 1 =male); age; average 24-hour frequency;
average 24-hour incontinence; number of stress incontin-
ence symptoms, pain symptoms, voiding symptoms and
OAB symptoms; the presence or absence of any pyuria
(0 = none, 1 = any pyuria); and the MSU culture result
(0 = negative, 1 = positive). In the second model we looked
more closely at the effect of the degree of pyuria. Pyuria
was grouped as zero pyuria, pyuria 1-9 or pyuria ≥10, sub-
groups which are currently used by most clinicians, and
these were referenced to control samples. The sample had
83% power to detect a .04 increment in R2, if ten predictor
variables were included in the regression model with
alpha = 0.05. In the laboratory experimental series, paired
data was collected and hence we used different statistical
analysis methods to the clinical experiment. We used the
paired t-test to analyse the difference in log10 ATP be-
tween paired samples stored at -20°C and -80°C; paired
samples stored with and without boric acid; and paired
samples centrifuged or uncentrifuged. The diagnostic
potential of urinary log10 ATP was assessed by ROC
plots using Positive MSU at 105 cfu ml-1 of a pure isolate
of a known urinary pathogen; pyuria ≥ 10 wbc μl-1 and
pyuria > 0 wbc μl-1.
Results
We compared urine samples from 75 healthy controls
and 340 patients presenting with LUTS. The demo-
graphic data can be seen in Table 1. The patients cohort
was grouped in the first model; with pyuria (≥1 wbc μl-1)
or without pyuria (0 wbc μl-1). For the second model weused categorical scaling so that we compared pyuria 1-9
wbc μl-1 (n = 120) and pyuria ≥10 wbc μl-1 (n = 120) with
a baseline factor of zero pyuria (0 wbc μl-1). Of those
with LUTS, 33.3% had only OAB symptoms, 4.1% had
pain alone, 3.7% had only stress incontinence and 13.2%
had only voiding dysfunction. Patients had a median of
3.5 LUTS (quartile range 1 to 6). The overlap of symp-
toms is illustrated in Figure 1.
Log10 transformation of ATP changed the skewness
from 4.2 to -0.3 and kurtosis from 27.5 to 1.1. The re-
sults of the two regression analyses are shown in Table 2.
It can be seen that female gender was associated with
higher predictions of the log10 ATP. However given the
small number of males and predominance of female
patients, which is a reflection of this condition, limited
discriminatory power precludes extrapolation. Voiding
symptoms were also predictive of higher log10 ATP. Inter-
estingly, voiding symptoms in both sexes have been re-
ported to be associated with inflammatory disease of the
lower urinary tract [22]. A positive culture result predicted
lower log10 ATP. The first regression model shows that
the presence of any pyuria was not predictive of higher
log10 ATP. The second regression model demonstrates
that a pyuria ≥10 wbc μl-1 was predictive of a higher log10
ATP; however, lower levels of pyuria 1-9 wbc μl-1 were
not. These data do demonstrate that urinary ATP is ele-
vated in association with inflammation but that urinary
ATP lacks the discriminating properties at lower levels of
pyuria, which are necessary for a useful clinical surrogate
marker. This is illustrated by the ROC analysis which
showed an area under the curve of 0.6 for a positive cul-
ture; 0.5 for pyuria > 0 wbc μl-1 and 0.6 for pyuria ≥ 10
wbc μl-1 (Figure 2). These data imply that there is no use-
ful diagnostic role for this assay. The regression analyses
showed that, age, average 24-hour frequency, average
24-hour incontinence, the number of urgency, stress in-
continence, and pain symptoms provided no substantial
explanation of the variance of urinary log10 ATP.
Urinary ATP decay over time
A subgroup of 20, randomly selected patient samples
was used to plot the urinary ATP concentration in sam-
ples at differing time points after collection; 0 hours,
12 hours, 24 hours, 48 hours, 168 hours. Aliquots were
taken at each point and frozen at -80°C and stored for as-
says in batches. The ATP concentration fell with time with
the rate of decline very dependent on the initial concen-
tration, as illustrated in Figure 3, where the time course of
each sample is plotted.
Urinary ATP and effect of storage with boric acid
preservative
Figure 4 shows box plots of the log10 ATP concentration
at each time point comparing the effect of boric acid.
Figure 1 Venn diagram of symptom analysis. A four-way Venn diagram illustrating the overlap of symptom amongst the patients studied. The
ellipses circumscribe patients who had one or more symptoms in the particular subset. The diagram is not scaled to the size of sets.
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strated the significance of this difference: mean log10 ATP
(moles) in samples stored without boric acid was -6.3
log10 moles and in samples stored at with boric acid
was -6.5 log10 moles (95% CI difference 0.15 to 0.29,
t = 6.2, p < .001). (Put significance at end of paragraph
as you did for the following paragraphs) These data
show that boric acid caused loss of ATP.
Urinary ATP and effect of storage temperature
Comparison of 30 paired samples of urine stored at -20°C
and -80°C showed no significant difference in ATP con-
centration: mean log10 ATP (moles) in samples stored
at -20°C was -6.7 log10 moles and in samples stored
at -80°C was -6.8 log10 moles (95% CI difference -0.09
to +0.01 , t = -1.7, p = .1). Thus storage at -20°C for 8 weeks
would seem reasonable.Urinary ATP and effect of centrifugation
Comparison of 30 paired samples of urine unspun and
spun showed that the supernatant urine had a slightly
lower level of ATP: mean log10 ATP (moles ml
-1) in
uncentrifuged samples = -6.9 log10 moles and in the super-
natant after centrifuge mean = -6.8 log10 moles (95% CI
difference 0.03 to 0.1, t = 3.5, p = .002). Whilst statistically
different, this is a very small difference and of little clinical
significance.
Discussion
ATP has been proposed as a potential clinical marker of
infection for both acute and chronic LUTS [10,27]. To
avoid premature use, when assessing the diagnostic po-
tential of test, it is important to assess first whether the
measure explains the symptoms and other manifesta-
tions of the disease of interest [28]. The data published
Table 2 Output from regression analysis
Model 1 pyuria described by dichotomy
95% confidence
interval for B




(Constant) -8.026 .000 -8.400 -7.652
Age .004 .197 -.002 .009
Gender 0 = female, 1 =male -.537 .001 -.865 -.209
MSU 0 = negative 1 = positive -.346 .004 -.582 -.110
Average 24-hour frequency -.004 .743 -.026 .019
Average 24-hour incontinence -.001 .990 -.092 .090
Number of stress incontinence
symptoms
-.065 .179 -.161 .030
Number of voiding symptoms .124 .000 .061 .187
Number of pain symptoms .082 .382 -.103 .267
Number of urgency symptoms -.030 .163 -.072 .012
Pyuria 0 = none 1 = any .157 .107 -.034 .349
Model 2 pyuria described by ordinal scale
95% confidence
interval for B




(Constant) -8.058 .000 -8.431 -7.685
Age .002 .404 -.003 .008
Gender 0 = female, 1 =male -.522 .002 -.845 -.199
MSU 0 = negative 1 = positive -.406 .001 -.642 -.171
Average 24-hour frequency -.002 .878 -.024 .021
Average 24-hour incontinence -.024 .607 -.114 .067
Number of stress incontinence
symptoms
-.060 .210 -.154 .034
Number of voiding symptoms .106 .001 .043 .169
Number of pain symptoms .085 .356 -.096 .266
Number of urgency symptoms -.024 .257 -.066 .018
Pyuria1 to 9 wbc μl-1 .207 .059 -.008 .422
Pyuria≥ 10 wbc μl-1 .432 .000 .203 .662
Dependent variable is urinary log10 ATP concentration
Figure 2 Receiver-operator characteristics (ROC) curve for
urinary ATP for the diagnosis of UTI. The ROC analysis shows an
area under the curve of 0.6 for pyuria≥ 10 wbc μl-1. These data
imply that there is no useful diagnostic role for this assay.
Figure 3 The ATP decay curves for a subset of 20 urine
samples. The rate of decay is substrate concentration dependent;
such that a sample with a higher ATP concentration shows a
more marked decay. It is therefore important to assay or freeze
immediately after collection of the urine specimen to preserve
the ATP signal.
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additional benefit to tests currently used in screening for
infection in patients presenting with LUTS, and there-
fore does not show promise for future development of a
diagnostic test for this particular group. This observation
is confirmed in the ROC curves that explore sensitivity
and specificity properties.
Our results demonstrate that patients with LUTS and
any pyuria do not manifest a significantly raised urine ATP
concentration. It is only when there is pyuria of greater
than 10 wbc μl-1, which is a currently used marker of urin-
ary infection, that there is a significantly raised urinaryATP. However, this signal was not a discriminating marker
for low levels of lower urinary tract inflammation (pyuria
1-9 wbc μl-1) as shown by our second regression model,
and it is in these clinical circumstances that there is great-
est need for novel clinical surrogate markers. It has been
shown that low-level pyuria [26], voiding symptoms [22],
overactive bladder symptoms [24] and pain symptoms [23]
all correlate with urinary infection. Only voiding symptoms
explained a small amount of the variance in ATP. These
findings are therefore discouraging.
Counter-intuitively, urinary ATP was lower, given a
positive urine culture. This unexpected result may reflect
Figure 4 A box plot showing the effects of boric acid preservative
on urinary ATP decay. The box plot shows a subset of 20 paired
samples to test the effect of boric acid as a urinary preservative
on the decay of urinary ATP. Urinary ATP was measured at 12 hour
intervals in urine samples with and without boric acid.
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that there weren’t enough data to draw meaningful con-
clusions. Increased microbial dephosphorylation of ATP
to adenosine, which we did not assay, may also be a con-
tributing factor. In addition, the urinary ATP reflects the
urinary microbial biomass directly post void and there
may be significant variation in the urinary biomass at the
time of culture secondary to transportation and process-
ing delay.
There was an unbalanced sample size with fewer con-
trol participants with a lower average age, and this re-
flects the common difficulty of finding older subjects
without any urinary tract symptoms. The controls in this
experiment were all asymptomatic. We did control for
these differences in the analysis but would nevertheless
wish to avoid wide inferential generalisations. The es-
sence of this study was to scrutinise the discriminating
properties amongst patients. The recruitment field was
also predominantly female which may explain the gender
difference. The small numbers of males were neverthe-
less included in the analysis as the model was sufficiently
powered for this variable, which required ≥20 for each
independent variable. The sample was powerful enough
to detect the influence of voiding symptoms, pyuria and
culture, despite the wide variance. Urinary ATP concen-
trations proved independent of age and the number and
nature of LUTS symptoms, other than voiding symp-
toms. The association with voiding symptoms was not
surprising because in patients with chronic LUTS,these have been reported to be correlated with pyuria
in both genders, in clear contrast to OAB and pain
symptoms [22].
We found that urinary ATP could not pick out low
levels of inflammation (pyuria 1-9 wbc μl-1) when used
alone, a situation where clinicians need most help.
Current dipstick methods and direct urinary microscopy
are able to identify pyuria when it is abundant [26], so
urinary ATP would offer no additional advantage. There
can be little doubt that ATP plays a very significant role
in the pathophysiology of urinary tract disease [29,30]
but it would seem that this does not translate into a use-
ful role as a clinical test when used alone.
The laboratory experimental series showed that urine
samples should be processed immediately or frozen and
stored at below -20°C. We demonstrated significant urin-
ary ATP decay with time when samples were left at room
temperature, with the rate being substrate dependent. We
also found that storage of urine at -20°C is adequate and
this therefore allows for wider use of standard freezers as
opposed to the specialised -80°C devices. The centrifuge
studies examined the effect of the removing cellular
material. The supernatant showed marginally lower levels
of ATP. This could be attributed to increased ATPase ac-
tivity from burst cells or it may have resulted from delayed
freezing, allowing additional time for enzyme activity.
Additionally, centrifugation results in the removal of bio-
mass and hence this may explain the lower levels of
urinary ATP. This marginal difference, though statisti-
cally significant, may not be clinically significant; never-
theless, centrifuging of urine prior to freezing or analysis
is an additional labour worth avoiding. Boric acid proved
counterproductive and so should not be used as a
preservative.
Conclusion
In summary these data discourage the idea that urinary
ATP should be developed as a clinical surrogate test for
UTI in patients presenting with LUTS. This assay does
not appear more effective than markers used in current
clinical practice [3,26]. However, abundant urinary ATP
is certainly evident amongst patients with lower urinary
tract symptoms and dysfunction and these data do en-
courage continued interest in the pharmacology and
pathophysiology of purinergic functions in the bladder.
For those committed to these avenues of discovery, we
provide valuable data on human sample processing, stor-
age and assay.
In conclusion, urinary ATP does not improve on the
use of microscopy as a surrogate marker of urinary tract
infection in patients presenting with LUTS and is there-
fore not a promising clinical diagnostic marker. We need
to continue to explore other potential markers that can
be used to screen LUTS patients for UTI, particularly
Gill et al. BMC Urology  (2015) 15:7 Page 8 of 9applicable to those that have lower levels of pyuria, where
significant disease may currently be overlooked [26]. The
relevance of measuring ATP to study the pathophysiology
of the lower urinary tract is still very evident and in that
context urine is a useful biological sample.
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